In a Phase I clinical trial of SOR-C13, a TRPV6 calcium channel inhibitor, two patients having advanced pancreatic cancer indicated a reduction in tumor, along with a 55% reduction in CA19–9 in one patient [30]. Here, TRPV6 is linked to familial pancreatic carcinoma.